Articles tagged with Clinical Trials
A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths. The ALIVE clinical trial showed higher cure rates for T. trichiura, hookworms, and improved egg reduction rates compared to albendazole alone.
The project aims to improve the design of clinical trials for neurological conditions like stroke, Parkinson's disease, and vascular cognitive impairment and dementia. Community partners will facilitate academic and community partnerships for clinical trial development.
A groundbreaking UK study found that using procalcitonin (PCT) to guide treatment decisions did not reduce antibiotic duration in hospitalized children. The PCT test was safe but costlier than standard methods, and healthcare teams faced challenges integrating it into their decision-making processes.
A new AI platform, TrialTranslator, helps clinicians and patients assess individual patient benefits from clinical trials by analyzing real-world data. The study reveals that machine learning can identify groups of patients in whom randomized controlled trial results are less generalizable.
A new study aims to address pain treatment disparities by empowering Black patients with chronic pain and depression to find safe, effective approaches. The EQUIPD intervention uses individual coaching to help patients work through different non-medication treatment options.
A new type of bioengineered blood vessel demonstrated superior infection resistance and better limb preservation compared to conventional synthetic grafts. The technology has the potential to reduce amputation numbers significantly, as it can be implanted immediately and is more resistant to infection than traditional options.
A systematic literature search identified high-priority clinical actions for post-acute care, including early education, risk assessment, and mental health screening. Implementing these actions can improve the quality of care for non-hospitalized TBI patients.
Researchers are investigating a water vapor system that uses small, targeted amounts of steam to kill cancer cells in patients with intermediate-risk prostate cancer. The trial aims to explore the safety and effectiveness of this treatment as an alternative to traditional therapies, which can cause life-altering side effects.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Engaging in 30 minutes of aerobic exercise per week modestly reduces body weight, waist circumference, and body fat measures. Aerobic training exceeding 150 minutes per week may be needed for clinically important reductions.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
Researchers at Vanderbilt University have successfully completed a phase I clinical trial of VU319, a drug that increases the efficacy of acetylcholine at the M1 receptor, showing promise as an Alzheimer's treatment. The trial demonstrated no side effects and target engagement at the highest dose tested.
A clinical trial showed that an antibody blocking Nogo-A protein improves motor function in patients with incomplete spinal cord injuries. The treatment led to significant improvements in voluntary muscle activation and everyday life functional independence. Further studies are needed to confirm the findings.
A randomized clinical trial found that a brief outpatient rehabilitation program improved physical function in patients with post-COVID condition. The intervention showed sustained benefits over time, with negligible adverse effects.
People with severe depression who received vagus nerve stimulation showed significant improvement in depressive symptoms, quality of life, and ability to complete everyday tasks after a year. Despite this, the therapy remains unaffordable for many patients due to high costs.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
The Keck School of Medicine of USC has joined the Ryght Research Network to leverage AI tools and optimize cancer clinical trials. The collaboration aims to offer more clinical trials to patients, build new AI tools, and speed up the development of medical treatments.
This randomized clinical trial suggests that transcutaneous auricular vagus nerve stimulation is a safe and effective treatment option for chronic insomnia. Future multicenter trials are needed to validate its effectiveness across different populations.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
A randomized clinical trial found that cannabidiol (CBD) significantly reduced anxiety levels 2-4 hours after ingestion in women with advanced breast cancer. CBD's anxiolytic effect suggests its potential as a treatment for scan-related anxiety.
The ZEST trial found that patients with detectable circulating tumor DNA (ctDNA) were more likely to have aggressive disease characteristics. To improve outcomes, researchers recommend starting ctDNA testing during treatment rather than waiting for completion, and targeting high-risk patients with tailored therapies.
Researchers from Kessler Foundation will evaluate the efficacy of Brain.Q's 'Q Therapeutic System' in a two-year study. The therapy involves electromagnetic stimulation and low-intensity fields to optimize brain adaptation and healing after stroke.
Women with low-risk ductal carcinoma in situ reported similar experiences undergoing active monitoring versus guideline-concordant care. The study found that both approaches had comparable lived experiences during the 2-year follow-up period.
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Researchers found no correlation between adenotonsillectomies and undesirable weight gain in children with mild sleep-disordered breathing. The study used data from a clinical trial involving 458 children and showed that adenotonsillectomy improved symptoms, blood pressure, and quality of life but not primary neurodevelopmental outcomes.
The OlympiA trial found that olaparib significantly improves survival outcomes in patients with high-risk, BRCA-positive breast cancer. After a median follow-up of 6.1 years, patients treated with olaparib showed better rates of invasive and distant disease-free survival compared to those who received placebo.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat was safe but did not improve mpox resolution or pain in adults with mild to moderate clade II mpox. The study recommended stopping further enrollment due to the lack of efficacy signal.
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
Dr. Aditya Bardia's appointment as Editor-in-Chief of Breast Cancer Research and Treatment reflects his expertise in targeted therapies and innovative research. He aims to foster innovation and disseminate knowledge benefiting patients and the scientific community through this journal.
A large clinical trial found that removing 10% of a patient's blood before major liver surgery reduces the need for transfusions by half. This practice, known as hypovolemic phlebotomy, lowers blood pressure in the liver and is safe, simple, and inexpensive.
The University of Cincinnati College of Medicine has launched a styrofoam recycling project to divert over 900 pounds of EPS waste from landfills each month. The program aims to reuse existing styrofoam materials, reducing the need for styrene and minimizing environmental impact.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
A pilot clinical trial is testing the effectiveness of noninvasive electrical brain stimulation as a cognitive rehabilitation method for traumatic brain injury (TBI). The study aims to determine how early treatment with targeted brain stimulation can enhance cognitive recovery in moderate to severe TBI.
Researchers will compare smaller vs. larger breathing tubes in 3,180 patients to assess long-term patient-centered outcomes and safety. The study aims to fill an evidence gap on the effect of breathing tube size on shortness of breath after critical illness.
A groundbreaking phase one clinical trial explores a novel cell-based immunotherapy for breast cancer, demonstrating significant shrinkage of tumors and minimal side effects. The treatment leverages dendritic cells to trigger an organized immune system attack on cancer, offering hope for replacing or reducing the need for chemotherapy.
The COPD Foundation's PIVOT initiative aims to integrate patient-inspired health concepts into clinical trials for COPD. This framework improves research study design, enhances treatment benefit communication, and accelerates access to new therapies.
Researchers reported positive long-term results of bilateral capsulotomy for severe obsessive-compulsive disorder treatment, with high patient satisfaction even at 10 years. The study suggests MRgFUS capsulotomy may also be effective in managing other psychiatric diseases.
A clinical trial led by University of Oklahoma Health Sciences is investigating a new device designed to restore ovulation in women with polycystic ovary syndrome (PCOS)-related infertility. The REBALANCE trial aims to assess the safety and effectiveness of the device, which uses electrothermal energy to prompt ovulation.
A Phase 2 clinical trial has been initiated by Genethon and Hansa Biopharma to evaluate the efficacy and safety of imlifidase, a gene therapy for Crigler-Najjar syndrome. The trial aims to address anti-AAV antibodies, which prevent up to 1 in 3 people from benefiting from gene therapies.
A large-scale clinical trial involving over 9,000 patients reveals that text message reminders failed to improve medication refill adherence over a year. The study included diverse representation from subgroups, including females, Hispanic ethnicity, and Spanish-speaking patients.
Researchers assess 20 years of clinical trials for cell therapy's safety and efficacy in treating heart failure, highlighting progress despite challenges. The field continues to evolve through lessons learned from past studies, with ongoing trials taking novel directions.
A recent clinical trial has revealed a twice-yearly injection of Lenacapavir to be 96% effective in preventing HIV infection, surpassing daily oral PrEP. The study included racially and ethnically diverse participants, highlighting the need for more options in HIV prevention.
The ESMO Asia Congress 2024 will focus on multidisciplinary oncology in the Asian region, featuring novel treatment modalities, management of specific cancer types and pan-Asian trials. Key highlights include insights into genetics, biology and practice differences between West and Asia.
Researchers at UCSF are enrolling patients in a clinical trial to correct the genetic mutation causing sickle cell disease using non-viral CRISPR-Cas9 gene editing. The therapy aims to eliminate the need for a bone marrow transplant and create a new blood system free of the disease.
A study estimates that approximately one-third of eligible US adults without diabetes were excluded from clinical trials supporting GLP-1 and GLP-1/GIP medications. The FDA should consider updating labeling to advise caution on generalizing these medications' safety and effectiveness to excluded populations.
The study found that irritability was the most common systemic reaction in children under 2 years, followed by fever and fatigue or sleepiness. Maternal vaccination is thought to be a factor in the higher prevalence of reactions after the first dose.
The updated ASTRO guideline recommends personalized treatment approaches for patients with locally advanced rectal cancer, including non-surgical alternatives and intensified treatment regimens. The guideline aims to improve outcomes while preserving quality of life.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
A phase 2b clinical trial found that sodium oxybate, an oral medication mimicking alcohol's effects, significantly improves symptoms of patients with laryngeal dystonia who respond to alcohol. The treatment provided up to 5 hours of voice relief, with no serious adverse events.
A University of Michigan-led study suggests that recycled pacemakers can be used safely and effectively in patients with life-threatening cardiac conditions. The international clinical trial involved nearly 300 people across seven countries and found no significant differences in pacemaker function up to 90 days after the procedure.
Positive initial results from Genethon's gene therapy GNT0004 show stabilization of motor functions and improved dystrophin expression in patients with Duchenne Muscular Dystrophy. The therapy is expected to be launched in pivotal trial phases in Europe and the US in Q2/2025.